Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €4.38 EUR
Change Today -0.124 / -2.75%
Volume 0.0
HTD On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 11:16 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

corcept therapeutics inc (HTD) Snapshot

Open
€4.53
Previous Close
€4.50
Day High
€4.57
Day Low
€4.38
52 Week High
06/22/15 - €6.77
52 Week Low
08/11/14 - €1.66
Market Cap
472.0M
Average Volume 10 Days
21.5
EPS TTM
--
Shares Outstanding
107.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORCEPT THERAPEUTICS INC (HTD)

corcept therapeutics inc (HTD) Related Bloomberg News

View More Bloomberg News

corcept therapeutics inc (HTD) Related Businessweek News

No Related Businessweek News Found

corcept therapeutics inc (HTD) Details

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

50 Employees
Last Reported Date: 03/13/15
Founded in 1998

corcept therapeutics inc (HTD) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $571.3K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $350.9K
Senior Vice President of Oncology
Total Annual Compensation: $397.4K
Consultant
Total Annual Compensation: $251.8K
Compensation as of Fiscal Year 2014.

corcept therapeutics inc (HTD) Key Developments

Corcept Therapeutics Inc Announces Executive Changes

Corcept Therapeutics Inc. announced retirement of Anne M. LeDoux Vice President, Controller and Chief Accounting Officer of the company with effective from July 1, 2015. The company also appointed G. Charles Robb, its Chief Financial Officer, to as Chief Accounting Officer, effective immediately. Robb has served as its Chief Financial Officer since September 2011 and as its Secretary since January 2014.

Corcept Therapeutics Incorporated Appoints Daniel N. Swisher as its Director

On June 18, 2015, the Board of Directors of Corcept Therapeutics Incorporated elected Daniel N. Swisher, Jr. to serve as a director of the company until the next annual meeting. Mr. Swisher was also appointed to the Audit Committee of the Board. He has been the Chief Executive Officer and a Board member of Sunesis Pharmaceuticals Inc. since 2003. Mr. Swisher joined Sunesis in 2001 and served as its Chief Business Officer and Chief Financial Officer before becoming CEO. Before that, Mr. Swisher held a broad range of senior management roles, including Senior Vice President of Sales and Marketing at ALZA Corporation from 1992 to 2001. Since 2013, he has also served as Chairman of the Board of Cerus Corporation.

Corcept Announces Results from Multi-Center Phase I/II Dose-Escalation Study of mifepristone and eribulin in Patients with Triple-Negative Breast Cancer

Corcept Therapeutics Incorporated has announced results from a multi-center Phase I/II dose-escalation study of mifepristone and eribulin in patients with triple-negative breast cancer. Patients with triple-negative breast cancer need better treatments and hopeful that mifepristone when combined with chemotherapy, will benefit them." Researchers enrolled 13 metastatic breast cancer patients for the first phase of the study to determine the maximum tolerated dose of the mifepristone-eribulin combination. The results showed that the combination regimen was well-tolerated with evidence of clinical activity for patients with triple-negative breast cancer (TNBC). The recommended Phase I/II dose of 300 mg of mifepristone daily with 1.1./mg/m2 of eribulin showed no evidence of a drug-drug interaction and will be used in the next phase of the study. An additional 20 patients with GR-positive metastatic TNBC will be enrolled into the study's efficacy phase. Although the dose-selection phase of the study was designed to assess only safety and tolerability, some preliminary efficacy data was produced. Patients with metastatic breast cancer (five with triple-negative breast cancer) were treated with mifepristone and eribulin at three different dose levels. The study consisted of seven patients with GR-positive tumors, three patients with GR-negative tumors and three patients with unknown GR status. Two partial responses have been observed, both in patients with GR-positive cancer. Of the 13 total patients in the study, four experienced neutropenia, leading to delay of eribulin. Grade 3/4 neutropenia was observed in nine patients but was easily managed. Neuropathy was observed in two patients. No other significant toxicity was noted in the study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HTD:GR €4.38 EUR -0.124

HTD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Novartis AG SFr.101.10 CHF +0.70
View Industry Companies
 

Industry Analysis

HTD

Industry Average

Valuation HTD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.9x
Price/Book 51.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORCEPT THERAPEUTICS INC, please visit www.corcept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.